eli lilly glp 1 injection Novo Nordisk Sues Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data Eli Lilly Orforglipron Diabetes Trial

doi: 10.1111/j.1365-2982.2009.01317.x 165 NishizawaMNakabayashiHUchidaKNakagawaANiijimaA

Authors: Patricia J

"You have some very paternalistic employers out there that believe in the efficacy of these drugs

doi: 10.3389/fendo.2025.1649270 Received 18 June 2025 Accepted 22 September 2025 Published 07 October 2025 Volume 16 - 2025 Edited by Lingling Wei, Capital Medical University, China Reviewed by Katy Sanchez-Pozos, Hospital Jurez de Mxico, Mexico Koyel Kar, BCDA College of Pharmacy and Technology, India brahim Sarbay, Gaziosmanpaa Training and Research Hospital, Trkiye Updates Copyright 2025 Gandecka-Pempera, Naskrt, Adamska and Zozuliska-Zikiewicz

The therapeutic potential of GLP-1 receptor agonists first gained attention due to their ability to help individuals with type 2 diabetes maintain blood glucose levels